Navigation Links
Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
Date:2/8/2010

SAN DIEGO, Feb. 8 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has appointed William H. Rastetter Ph.D. to its Board of Directors effective immediately. He is the current Chairman and Chief Executive Officer of Receptos, Inc., and former Executive Chairman of Biogen Idec, Inc.

"We are very pleased to welcome Bill Rastetter to our Board of Directors," said Joseph A. Mollica, Ph.D., Chairman of the Board of Neurocrine Biosciences.  "The company is very fortunate to have someone with Bill's experience and proven track record in the biotech industry. He will be a valuable resource to Neurocrine as the Company moves forward."

Dr. Rastetter is currently the Chairman and Chief Executive Officer of Receptos, a privately-held drug discovery and development company which utilizes pioneering G protein-coupled receptor (GPCR) technology, including 3-dimensional structure determination of these membrane bound proteins, to facilitate information-driven drug design for developing best- and first-in-class drugs. He is also currently the Chairman of the Board of Directors of Illumina, Inc., and is a partner in the venture capital firm Venrock.

Dr. Rastetter retired as the Executive Chairman of Biogen Idec Inc., a biopharmaceutical company, at the end of 2005 and had served in that position since the November 2003 merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation. He served as Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003 and as chairman of the Board of Directors from May 1996 to November 2003. Additionally, he served as President of IDEC Pharmaceuticals from 1986 to 2002 and as Chief Financial Officer from 1988 to 1993. From 1982 to 1986 Dr. Rastetter served in various positions at Genentech, Inc., a biotechnology company, and prior to Genentech he was an associate professor at the Massachusetts Institute of Technology.

Rastetter earned a Ph.D. from Harvard University in 1975.  He also holds a Masters of Arts in Chemistry from Harvard University and a Bachelor of Science degree in Chemistry from Massachusetts Institute of Technology.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

SOURCE Neurocrine Biosciences, Inc.

RELATED LINKS
http://www.neurocrine.com

'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
2. Neurocrine Biosciences Amends Corporate Headquarters Lease
3. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
4. Neurocrine Biosciences Secures Committed Equity Financing Facility
5. Neurocrine Biosciences Reports Second Quarter 2009 Results
6. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
8. Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference
9. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
10. Neurocrine Biosciences Reports First Quarter 2009 Results
11. Neurocrine Announces Work Force Restructuring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
Breaking Biology Technology:
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):